Biondi Bernadette, Cooper David S
Department of Clinical and Molecular Endocrinology and Oncology, University of Naples Federico II, Via S. Pansini 5, 80131 Naples, Italy.
Endocr Rev. 2008 Feb;29(1):76-131. doi: 10.1210/er.2006-0043. Epub 2007 Nov 8.
Subclinical thyroid disease (SCTD) is defined as serum free T(4) and free T(3) levels within their respective reference ranges in the presence of abnormal serum TSH levels. SCTD is being diagnosed more frequently in clinical practice in young and middle-aged people as well as in the elderly. However, the clinical significance of subclinical thyroid dysfunction is much debated. Subclinical hyper- and hypothyroidism can have repercussions on the cardiovascular system and bone, as well as on other organs and systems. However, the treatment and management of SCTD and population screening are controversial despite the potential risk of progression to overt disease, and there is no consensus on the thyroid hormone and thyrotropin cutoff values at which treatment should be contemplated. Opinions differ regarding tissue effects, symptoms, signs, and cardiovascular risk. Here, we critically review the data on the prevalence and progression of SCTD, its tissue effects, and its prognostic implications. We also examine the mechanisms underlying tissue alterations in SCTD and the effects of replacement therapy on progression and tissue parameters. Lastly, we address the issue of the need to treat slight thyroid hormone deficiency or excess in relation to the patient's age.
亚临床甲状腺疾病(SCTD)的定义为:在血清促甲状腺激素(TSH)水平异常的情况下,血清游离甲状腺素(T4)和游离三碘甲状腺原氨酸(T3)水平处于各自的参考范围内。在临床实践中,越来越多的年轻人、中年人和老年人被诊断出患有亚临床甲状腺疾病。然而,亚临床甲状腺功能障碍的临床意义仍存在诸多争议。亚临床甲状腺功能亢进和减退会对心血管系统、骨骼以及其他器官和系统产生影响。然而,尽管亚临床甲状腺疾病有进展为显性疾病的潜在风险,但对于其治疗、管理以及人群筛查仍存在争议,对于考虑进行治疗时甲状腺激素和促甲状腺激素的临界值也没有达成共识。在组织效应、症状、体征和心血管风险方面,观点也存在差异。在此,我们对亚临床甲状腺疾病的患病率、进展、组织效应及其预后影响的数据进行批判性回顾。我们还研究了亚临床甲状腺疾病组织改变的潜在机制以及替代疗法对疾病进展和组织参数的影响。最后,我们探讨了根据患者年龄治疗轻微甲状腺激素缺乏或过量的必要性问题。